Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). Show More...

  • Website https://www.syndax.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 10.54 USD
  • Last Updated 30-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share USD -0.14 -7.55 -2.75 -5.98 -3.22 -2.9 -2.92 -1.84 -1.87
    Dividends USD
    Payout Ratio % *
    Shares Mil 70.0 8.0 10.0 17.0 15.0 21.0 25.0 30.0 32.0
    Book Value Per Share * USD 5.15 3.97 2.59 1.62 1.48
    Free Cash Flow Per Share * USD -1.61 -2.31 -2.69 -1.81
    Return on Assets % -659.93 -95.6 -144.13 -42.52 -47.33 -49.39 -66.9 -76.02 -55.71
    Financial Leverage (Average) 1.3 1.32 1.58 2.01 1.97
    Return on Equity % -64.53 -94.0 -132.43 -93.31
    Return on Invested Capital % -64.53 -94.0 -129.68 -79.1
    Interest Coverage -14.31
    Current Ratio 0.03 5.33 1.2 18.16 10.47 8.45 5.18 3.39 5.55
    Quick Ratio 0.03 5.22 1.18 18.06 10.19 8.25 5.04 3.26 5.28
    Debt/Equity 0.010 0.38